Patient adherence in COPD

被引:376
作者
Bourbeau, J. [1 ]
Bartlett, S. J. [1 ,2 ]
机构
[1] McGill Univ, Ctr Hlth, Montreal Chest Inst, Resp Epidemiol & Clin Res Unit, Montreal, PQ H2X 2P4, Canada
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
关键词
D O I
10.1136/thx.2007.086041
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Patient adherence to treatment in chronic obstructive pulmonary disease (COPD) is essential to optimise disease management. As with other chronic diseases, poor adherence is common and results in increased rates of morbidity, healthcare expenditures, hospitalisations and possibly mortality, as well as unnecessary escalation of therapy and reduced quality of life. Examples include overuse, underuse, and alteration of schedule and doses of medication, continued smoking and lack of exercise. Adherence is affected by patients' perception of their disease, type of treatment or medication, the quality of patient provider communication and the social environment. Patients are more likely to adhere to treatment when they believe it will improve disease management or control, or anticipate serious consequences related to non-adherence. Providers play a critical role in helping patients understand the nature of the disease, potential benefits of treatment, addressing concerns regarding potential adverse effects and events, and encouraging patients to develop self-management skills. For clinicians, it is important to explore patients' beliefs and concerns about the safety and benefits of the treatment, as many patients harbour unspoken fears. Complex regimens and polytherapy also contribute to suboptimal adherence. This review addresses adherence related issues in COPD, assesses current efforts to improve adherence and highlights opportunities to improve adherence for both providers and patients.
引用
收藏
页码:831 / 838
页数:8
相关论文
共 86 条
[1]   Adherence intervention research: What have we learned and what do we do next? [J].
Bender, B ;
Milgrom, H ;
Apter, A .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 112 (03) :489-494
[2]   Adherence and persistence with fluticasone propionate/salmeterol combination therapy [J].
Bender, Bruce G. ;
Pedan, Alex ;
Varasteh, Laleh T. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (04) :899-904
[3]  
Blais Lucie, 2004, Can Respir J, V11, P27
[4]   Self-management and behaviour modification in COPD [J].
Bourbeau, J ;
Nault, D ;
Dang-Tan, T .
PATIENT EDUCATION AND COUNSELING, 2004, 52 (03) :271-277
[5]   Disease-specific self-management programs in patients with advanced chronic obstructive pulmonary disease - A comprehensive and critical evaluation [J].
Bourbeau, J .
DISEASE MANAGEMENT & HEALTH OUTCOMES, 2003, 11 (05) :311-319
[6]  
BOURBEAU J, 2003, CAN RESPIR J, V10, P207
[7]   Economic benefits of self-management education in COPD [J].
Bourbeau, Jean ;
Collet, Jean-Paul ;
Schwartzman, Kevin ;
Ducruet, Thierry ;
Nault, Diane ;
Bradley, Carole .
CHEST, 2006, 130 (06) :1704-1711
[8]   Intervention-related cognitive versus social mediators of exercise adherence in the elderly [J].
Brassington, GS ;
Atienza, AA ;
Perczck, RE ;
DiLorenzo, TN ;
King, AC .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2002, 23 (02) :80-86
[9]   Persistence with inhaled corticosteroid therapy in daily practice [J].
Breekvedt-Postma, NS ;
Gerrits, CMJM ;
Lammers, JWJ ;
Raaijmakers, JAM ;
Herings, RMC .
RESPIRATORY MEDICINE, 2004, 98 (08) :752-759
[10]   Enhanced persistence with tiotropium compared with other respiratory drugs in COPD [J].
Breekveldt-Postma, Nancy S. ;
Koerselman, Jeroen ;
Erkens, Johe A. ;
Lammers, Jan-Willem J. ;
Herings, Ron M. C. .
RESPIRATORY MEDICINE, 2007, 101 (07) :1398-1405